Morning Industry Symposium:
The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer

Supported by AstraZeneca

Friday, October 14, 2022                                                                                                                                                                     Hall A (Great Hall 1)
07:30-08:30
Breakfast will be served from 07:00-07:30, half an hour prior to the start of the session.
Admission to this symposium is included as part of the congress registration

Chairperson: Belinda Yeo, Melbourne, Australia
07:30-07:35 Welcome and Introduction
Belinda Yeo, Melbourne, Australia
07:35-08:05 The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer

  • Enhertu DESTINY Breast-03
  • HER2+ mBC International Guideline updates
  • Treatment of CNS disease
  • Monitoring, Diagnoses and Managing of AE’s

Javier Cortes, Madrid, Spain
08:05-08:25 Panel discussion: Australian real-world considerations and the place of Enhertu (T-DXd) in treatment of HER2-positive Metastatic Breast Cancer
Richard de Boer, Melbourne, Australia
Nicole McCarthy, Brisbane, Australia
08:25-08:30 Questions
Skip to content